Keyword

palbociclib

Description: An anticancer drug that inhibits cyclin-dependent kinases 4 and 6, used in treatment of certain hormone receptor-positive breast cancers.

Primary topic: Advanced Breast Cancer Therapies (57%)

Wikidata ID: wiki/Q15269707

OpenAlex ID: keywords/palbociclib

Palbociclib and Letrozole in Advanced Breast Cancer

2016 · Richard S. Finn, Miguel Martin, et al. · New England Journal of Medicine · 2,986

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 · Richard S Finn, John P Crown, et al. · The Lancet Oncology · 1,895

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 · Massimo Cristofanilli, Nicholas C Turner, et al. · The Lancet Oncology · 1,817

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

2015 · Nicholas C. Turner, Jungsil Ro, et al. · New England Journal of Medicine · 1,583

PDF

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

2009 · Richard S Finn, Judy Dering, et al. · Breast Cancer Research · 1,395

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 · Nicholas C. Turner, Dennis J. Slamon, et al. · New England Journal of Medicine · 1,272

PDF

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

2004 · David W. Fry, Patricia J. Harvey, et al. · Molecular Cancer Therapeutics · 1,228

Treating cancer with selective CDK4/6 inhibitors

2016 · Ben O'Leary, Richard S. Finn, et al. · Nature Reviews Clinical Oncology · 1,128

Targeting CDK4 and CDK6: From Discovery to Therapy

2015 · Charles J. Sherr, David Beach, et al. · Cancer Discovery · 932

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

2016 · Charlotte Fribbens, Ben O’Leary, et al. · Journal of Clinical Oncology · 719

Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM

2017 · Kurt Engeland · Cell Death and Differentiation · 656

PDF

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

2018 · Ben O'Leary, Rosalind J. Cutts, et al. · Cancer Discovery · 653

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

2016 · Hope S. Rugo, R. Bryan Rumble, et al. · Journal of Clinical Oncology · 634

The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer

2020 · Lei Ding, Jiaqi Cao, et al. · International Journal of Molecular Sciences · 618

PDF

Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

2005 · Peter L. Toogood, Patricia J. Harvey, et al. · Journal of Medicinal Chemistry · 507

Targeting CDK4/6 in patients with cancer

2016 · Erika Hamilton, Jeffrey R. Infante · Cancer Treatment Reviews · 481

PDF

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

2020 · Laura M Spring, Seth A Wander, et al. · The Lancet · 471

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

2019 · Nicholas C. Turner, Yuan Liu, et al. · Journal of Clinical Oncology · 451

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

2019 · H. S. Rugo, R. S. Finn, et al. · Breast Cancer Research and Treatment · 440

PDF

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

2020 · C. Louwrens Braal, Elisabeth M. Jongbloed, et al. · Drugs · 439

PDF

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

2016 · Ping Chen, Nathan V. Lee, et al. · Molecular Cancer Therapeutics · 429

Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery

2022 · Yutian Zou, Jindong Xie, et al. · International Journal of Surgery · 426

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

2018 · Ben O’Leary, Sarah Hrebien, et al. · Nature Communications · 415

PDF

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

2019 · Luigi Formisano, Yao Lu, et al. · Nature Communications · 409

PDF

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

2013 · Mark A. Dickson, William D. Tap, et al. · Journal of Clinical Oncology · 399

Works count: 7,899

Citation count: 104,900